Singapore, June 10 -- Swedish biotech company Salipro Biotech AB has entered into a research collaboration with South Korea headquartered Daewoong Pharmaceutical Co.

Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro(R) platform for stabilising challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs.

Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech's expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein...